Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Politics

HHS SEC ROBERT F KENNEDY JR: American patients pay more so others can pay less — that stops now

by May 17, 2025
May 17, 2025
HHS SEC ROBERT F KENNEDY JR: American patients pay more so others can pay less — that stops now

NEWYou can now listen to Fox News articles!

President Donald Trump’s bold executive order on drug pricing isn’t just policy—it’s a revolution in healthcare affordability. The plan is simple yet transformative: ensure Americans pay no more for medications than citizens of other wealthy nations.

Consider this stark reality: a GLP-1 drug costing $88 in London commands $1,000 in the United States. Even after manufacturer discounts to insurers, Americans still pay over $400—for the identical medication, from the same company, produced in the same facility. This disparity is especially galling when pharmaceutical companies extract 70% of their profits from America—a nation representing just 4% of the world’s population. This global free-riding on American patients ends now.

Industry leaders recognize this imbalance. I’ve already engaged with CEOs from four major American pharmaceutical companies and a foreign manufacturer eager to relocate to the U.S. Their response has been encouraging, but we’re prepared to act decisively if necessary. U.S. Health and Human Services and Centers for Medicare & Medicaid Services (CMS) possess the statutory authority to deliver on President Trump’s commitment: other developed nations must pay more, so Americans can pay less, thus preserving the innovation pipeline.

Americans deserve both groundbreaking therapies and affordable access to them. Yet according to the Kaiser Family Foundation, nearly one-third of patients skip prescribed medications due to cost—an unacceptable reality in the world’s wealthiest nation.

Trump signs executive order lowering pharmaceutical drug prices for Americans

While prevention through healthier lifestyles remains our best strategy for reducing medication dependence, certain treatments will always be essential. The pharmaceutical industry has delivered remarkable advancements in cancer and autoimmune therapies that benefit patients worldwide. 

We value continued innovation as a core American principle, but we cannot indefinitely subsidize global medical progress while other wealthy nations contribute disproportionately little.

President Trump’s negotiation approach has already proven effective with NATO, where European countries responded to accountability by making historic reinvestments that strengthened the alliance. The same principle applies here. The President and I stand united: global free riding on American patients must end.

CMS, with Dr. Mehmet Oz at the helm, extends beyond payment reform to fundamentally realigning care delivery incentives. This initiative will protect safety nets for vulnerable populations while addressing the financial pressures facing state partners and federal programs—particularly Medicaid, which has seen dramatic growth in both enrollment and costs.

The coming months will be decisive in achieving President Trump’s prescription for a healthier America—one where innovation thrives, and patients no longer shoulder an unfair share of the global healthcare burden.

This post appeared first on FOX NEWS
previous post
Boeing would avoid guilty plea, prosecution over 737 Max crashes in possible DOJ deal
next post
JONATHAN TURLEY: Biden not the only loser revealed by shocking Hur audio

Related Posts

Biden says DNC anti-Israel agitators ‘have a point,’...

August 20, 2024

Emmanuel Macron calls ’emergency meeting’ for European leaders...

February 16, 2025

Trump picks Billy Long to head IRS, Kelly...

December 5, 2024

Trump admin fires Navy admiral at NATO targeted...

April 8, 2025

Trump budget bill with $4.5T in tax cuts...

February 14, 2025

Judicial pushback on Trump ‘hurting American people,’ says...

February 25, 2025

SCOOP: White House rallies House GOP on Trump...

April 3, 2025

Pritzker trolls Trump by ‘renaming’ Lake Michigan as...

February 8, 2025

Musk blasts Soros in series of posts after...

January 10, 2025

US swaps prisoners with China, releasing 3 convicted...

December 14, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • Biden interview audio reveals who brought up Beau’s death — and it wasn’t Hur

      May 17, 2025
    • ‘Failure’s not an option’: Trump budget bill will be ‘big’ help for seniors, top House tax-writer says

      May 17, 2025
    • Middle East trip highlights President Donald Trump’s 17th week in office

      May 17, 2025
    • JONATHAN TURLEY: Biden not the only loser revealed by shocking Hur audio

      May 17, 2025
    • HHS SEC ROBERT F KENNEDY JR: American patients pay more so others can pay less — that stops now

      May 17, 2025
    • Boeing would avoid guilty plea, prosecution over 737 Max crashes in possible DOJ deal

      May 17, 2025

    Categories

    • Business (1,217)
    • Politics (5,587)
    • Stocks (904)
    • World News (455)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved